These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19930409)

  • 21. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial.
    Singh JA; Mahowald ML; Noorbaloochi S
    Transl Res; 2009 May; 153(5):205-16. PubMed ID: 19375681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations.
    Kane M; Donofrio L; Ascher B; Hexsel D; Monheit G; Rzany B; Weiss R
    J Drugs Dermatol; 2010 Jan; 9(1 Suppl):s7-22; quiz s23-5. PubMed ID: 20919448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
    Moy R; Maas C; Monheit G; Huber MB;
    Arch Facial Plast Surg; 2009; 11(2):77-83. PubMed ID: 19289677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical applications of a new botulinum toxin.
    Hexsel D; Spencer JM; Woolery-Lloyd H; Gilbert E
    J Drugs Dermatol; 2010 Mar; 9(3 Suppl):s31-7. PubMed ID: 20361474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
    Brandt F; Swanson N; Baumann L; Huber B
    Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.
    Jongerius PH; van den Hoogen FJ; van Limbeek J; Gabreëls FJ; van Hulst K; Rotteveel JJ
    Pediatrics; 2004 Sep; 114(3):620-7. PubMed ID: 15342830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxins for facial wrinkles: beyond glabellar lines.
    Dayan SH; Maas CS
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):41-9, vi. PubMed ID: 17317554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection.
    Ascher B; Zakine B; Kestemont P; Baspeyras M; Bougara A; Niforos F; Malet T; Santini J
    Aesthet Surg J; 2005; 25(4):365-75. PubMed ID: 19338833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safe botulinum toxin type A injection in patients with history of eyelid ptosis.
    Ghalamkarpour F; Aghazadeh Y; Odabaei G
    J Cosmet Dermatol; 2009 Jun; 8(2):98-102. PubMed ID: 19527332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.
    Li X; Sui C; Xia X; Chen X
    Aesthetic Plast Surg; 2023 Feb; 47(1):365-377. PubMed ID: 36097079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes.
    Carruthers J; Carruthers A
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S10-7. PubMed ID: 17241408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular biology of botulinum neurotoxin serotype A: a cosmetic perspective.
    Eapen BR
    J Cosmet Dermatol; 2008 Sep; 7(3):221-5. PubMed ID: 18789058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
    Petri S; Tölle T; Straube A; Pfaffenrath V; Stefenelli U; Ceballos-Baumann A;
    Eur Neurol; 2009; 62(4):204-11. PubMed ID: 19622887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
    Evers S; Vollmer-Haase J; Schwaag S; Rahmann A; Husstedt IW; Frese A
    Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
    Oeconomou A; Madersbacher H; Kiss G; Berger TJ; Melekos M; Rehder P
    Eur Urol; 2008 Oct; 54(4):765-75. PubMed ID: 18571306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
    Schlessinger J; Monheit G; Kane MA; Mendelsohn N
    Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of botulinum toxin type A in children younger than 2 years.
    Pascual-Pascual SI; Pascual-Castroviejo I
    Eur J Paediatr Neurol; 2009 Nov; 13(6):511-5. PubMed ID: 19036619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.